NPR1多肽抗体的制备和应用

根据NCBI GenBank中报道的NPR1一级结构信息,采用Blastn、Blastx、ExPASy和Protean等软件进行序列同源性和抗原性指数分析,获得三段序列特异性较高的多肽,并从中优选一段序列特异性多肽,采用9-氟甲氧羰基固相合成法获得序列特异性最好的多肽,采用HPLC和LC-MS测定合成多肽的浓度和分子量,试验表明目的多肽纯度达88%、目的多肽分子量为1.92234 kD。采用碳化二亚胺法将多肽与KLH进行偶联获得免疫原Pep-KLH,并将其免疫新西兰大白兔以获得抗血清和多克隆抗体,采用ELISA和Western blotting测定其效价和特异性,经ELISA检测表明抗血清和多克隆抗体可与Pep发生特异性免疫反应,经Western blotting试验表明抗血清和多克隆抗体可识别烟草叶片特异性条带,其相对分子量为65 kD,与预测分子量相符,表明利用该方法制备的NPR1多肽抗体具有较高特异性和灵敏度。     

一种多肽固相合成方法与纯化策略研究

目的: 多肽与小分子化学药物相比,具有生物活性高、特异性强、不容易产生耐药性等特点,是目前新型药物研发的重点领域。多肽的合成直接影响到多肽药物的作用机制以及药物效果,因此需要建立一种更加便捷、高效的多肽合成方法。方法: 采用Fmoc固相合成法合成多肽HF01,通过比较氨基酸连接的反应体系以及氨基酸脱保护的反应体系,从中确定最优体系。利用乙酰化基团进行肽链末端保护,经肽链剪切制备干燥的粗肽,最后采用高效液相色谱仪与高分辨质谱仪联用对粗肽进行纯化。结果: 确定多肽合成的连接和脱保护反应体系,并获得纯度高达98.3%的线性多肽。结论: 建立了一种高效、便捷的多肽合成及纯化方法,提高了实验室合成多肽的效率,为多肽类药物的研发提供技术支撑。     

α- 促黑激素的固相合成研究

目的:探索α-促黑激素的合成工艺。方法:采用多肽固相合成法制备α-促黑激素。以Rink amide-MBHA树脂为载体、使用Fmoc保护策略、TBTU、HOBt、DIEA为缩合剂体系,最后用TFA、苯甲硫醚、水、苯酚、乙二硫醇混合液将多肽从树脂上切割下来。结果:合成后的目标多肽产率达64.9%,经过RP-HPLC纯化纯度可达98%,质谱鉴定显示纯化产物与目标多肽理论相对分子质量一致。结论:该方法操作方便,反应结果稳定,为固相合成生产α-促黑激素提供了一种可行的工艺方案。     

Fmoc固相合成JFT的工艺研究

目的:研究多肽JFT的合成工艺。方法:本实验采用固相合成法(spps),以Fmoc—氨基酸为原料,TBTU\HoBt\DIEA混合试剂缩合,用三氟乙酸\苯甲硫醚\巯基乙醇\苯酚\水脱保护,将多肽从MBHA树脂上切割下来。结果:粗肽的收率为62%,经RP-HPLC纯化,即可获得纯度在98%以上的目标肽。经MALDI—MS质谱分析其分子量与理论值一致。结论:此工艺操作简单,便于推广,适合大规模生产。     

戊肝病毒活性肽的选择,合成与应用

对戊型肝炎病毒（ＨＥＶ）编码蛋白序列进行了亲水性分析及二级结构预测,选择亲水性强、具有β－转角与β－折叠的区段,采用多肽固相合成法合成了ＨＥＶ基因组３个开读框架（ＯＲＦ１,ＯＲＦ２和ＯＲＦ３）中可能的抗原表位,以免疫学方法进行鉴定并选出了分别来自ＨＥＶ３个ＯＲＦ的、具有重要生物活性与应用前景的３段肽（ＥＨ１７４、ＥＨ２６５、ＥＨ３６２）。在此基础上,进行了抗ＨＥＶＥＬＩＳＡ新型检测试剂盒的实验室研究及临床试用。结果表明,所研究的戊肝抗体检测试剂盒特异性高、临床符合性好、具有可重复性,在戊肝辅助诊断及流行病学调查中具有重要意义。     

两种树脂固相合成机体保护肽的比较

目的:比较Wang树脂和二氯三苯甲基树脂(以下简称二氯树脂)在固相合成机体保护肽中的表现,为工业化生产提供理论依据。方法:通用的Fmoc固相合成法制备机体保护肽,通过比色法对两种树脂与氨基酸的偶联率进行比较,用质谱(MALDI-TOFMS)对粗肽进行鉴定分析,用反相高效液相色谱(RP-HPLC)进行粗肽的分析和纯化。结果:显示以二氯树脂作载体,第一个氨基酸的连接率,以及机体保护肽的纯度和产率都要明显高于Wang树脂。结论:二氯树脂作载体合成机体保护肽更适合大规模工业化生产的要求。     

兔抗弓形虫CorA家族Mg~(2+)转运蛋白多肽抗体的制备及鉴定

目的:制备并鉴定兔抗弓形虫CorA家族Mg~(2+)转运蛋白(TgMg)的特异性多克隆抗体。方法:设计并合成一段的具有较好免疫原性的、来源于TgMg氨基酸序列的短肽,短肽与KLH偶联后免疫新西兰大耳白兔,收集兔血清并分离纯化TgMg多克隆抗体,利用间接ELISA、Western印迹、间接免疫荧光等多种分子生物学方法鉴定多抗的效价、特异性及TgMg蛋白的亚细胞定位。结果:间接ELISA测定多抗效价为1∶160000;Western印迹显示该多抗能识别相对分子质量约为174×103的单一条带,表明抗体的特异性较好;用间接免疫荧光法发现TgMg定位于细胞质,与预期结果相符。结论:运用人工合成多肽结合经典的多克隆抗体制备技术制备了抗TgMg多克隆抗体,为深入研究TgMg蛋白的生物学特性及代谢功能提供了有效工具。     

抗人白细胞介素15中和抗体识别抗原表位的噬菌体肽库筛选与鉴定

目的:用噬菌体呈现随机七肽库筛选能与抗人白细胞介素15(h IL-15)中和抗体特异性结合的模拟抗原表位肽,并初步鉴定其免疫原性。方法:以抗h IL-15中和抗体为靶分子,用生物淘洗法从噬菌体呈现线性七肽库中筛选与之结合的噬菌体克隆,用噬菌体ELISA和竞争抑制ELISA鉴定阳性噬菌体克隆;化学合成筛选得到的多肽,并与匙孔血蓝蛋白(KLH)偶联免疫BALB/c小鼠,检测其免疫原性。结果:经过3轮体外筛选后随机挑取50个阳性噬菌体克隆,ELISA检测结果显示其中15个克隆与抗h IL-15抗体有较强的结合能力,DNA测序结果得到的结构相似群为MTPFWQK、MSPFNQK、MIPYWQK和MIPFHQK;竞争性ELISA结果显示4个序列均能与IL-15竞争性地结合抗IL-15单抗;小鼠免疫实验结果显示4组多肽均能诱导IL-15特异性免疫反应。结论:筛选得到能与抗h IL-15中和抗体特异性结合,且具有免疫原性的模拟抗原7肽序列,为进一步开发h IL-15相关的多肽疫苗提供了依据。     

模拟表位结合夹心化学发光法检测抗A和抗B效价

目的:获得A/B血型抗原的模拟多肽,并将其与夹心化学发光免疫分析(chemiluminescence immunoassay, CLIA)相结合,以开发更有效的方法来测量A/B抗体的效价。方法:分别用NaM87-1F6和HEB-29对噬菌体12肽库进行三轮淘选。对经酶联免疫吸附实验(ELISA)确定的阳性菌斑进行测序分析,根据其氨基酸组成合成模拟多肽,并通过竞争性ELISA、凝集抑制等方法检测其抗原性。随后将获得的模拟多肽与CLIA结合,检测A、B抗体效价,制作标准曲线以及与现有的微柱凝胶法(CAT)进行相关性对比。结果:经过三轮淘选和相关鉴定后得到13个与抗A抗体和19个与抗B抗体特异性相互作用的噬菌体克隆,其中分别有9个(MTRIQLRMMRLH)和12个(PQMSRHRMRMLP)展示相同的氨基酸序列,据此合成的多肽分别命名为MTR和PQM。竞争性ELISA结果表明,MTR能够特异性拮抗A抗体和A抗原的替代多肽的免疫结合;PQM能够特异性拮抗B抗体和B抗原的替代多肽的免疫结合。凝集抑制实验表明MTR/PQM可以特异性抑制A/B型红细胞与抗A/B之间的相互作用。结合模拟肽的夹心CLIA具有较宽的线性范围(2-2048)和良好的线性相关系数(对于A抗体R~2=0.9566,对于B抗体R~2=0.9762)。基于CLIA方法和CAT测得的抗体滴度结果高度相关(P0.001)。结论:MTR和PQM有良好的A或B抗原性,具有成为其人工替代品的潜能。模拟多肽与夹心CLIA相结合能够实现对A、B抗体滴度的定量检测,且其结果准确可靠。     

生物活性肽SSDI固相合成工艺的研究

目的:研究生物活性肤SSDI的固相合成工艺,并为大规模合成目标肽提供理论依据.方法:采用固相合成法,原料氨基酸以Fmoe形式保护,用Wang树脂为载体,经1-氧3-双二甲胺羰基苯骈三氮唑四氟化硼盐(TBTU)\1-羟基-苯并-三氮唑(HOBt)\二-异丙基乙胺(DIEA)混合试剂缩合,20%哌啶的DMF溶液脱保护,用三氟乙酸\茴香硫醚\巯基乙醇\苯酚\水混合作为切割试剂将多肽从Wang树脂上切割下来.结果:多肽粗品的得率高达70%,经RP-HPLC纯化,可获得纯度在98%以上的目标肽,经MALDI-MS质谱鉴定其分子量与理论值一致.结论:此合成方法操作简单,产品得率高,适合大规模合成目标肽.     

Synthetic Peptides are Better Than Native Antigens for Development of ELISA Assay for Diagnosis of Tuberculosis

Immunodiagnosis of both pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis has remained challenging. In the present work, in-house developed synthetic peptide based antibody detection assay was assessed and validated with antigen based assay for effective diagnosis of tuberculosis (TB). The study population included both tuberculous meningitis (TBM) (n = 60) admitted to Neurology IPD wards of our Institute hospital and PTB cases (n = 57) recruited from high TB endemic zones. Peptides of five highly immunogenic Mycobacterium tuberculosis (MTB) proteins (Ag85B, 45 kDa, HSP-16, CFP-10 and ESAT-6) were designed and synthesized. The designed peptides were evaluated in samples of both TBM and PTB cases, respectively, using in-house developed antibody detection method. The developed tests were further compared and validated with MTB native proteins based antibody detection ELISA. Sensitivity and specificity of peptide assay were significantly higher or almost similar (p < 0.05) in TBM and PTB as compared to native proteins based ELISA. Among all peptides, diagnostic reliability of Ag 85B peptide A1 was higher for both forms of TB. Peptide-based antibody assay is cost effective, simple and may be interchangeable with conventional Antigen based ELISA assays for effective diagnosis of TB in the developing world.     

合成肽抗原在戊型肝炎病毒感染诊断中的应用

An ELISA for the detection of anti HEV using synthetic peptide antigens was developed. The synthetic antigens were encoded by OFR2 and OFR3 genes of HEV. The purpose of this study was to determine the applicability of the synthetic antigens in the serodiagnosis of hepatitis E. The anti HEV detection using synthetic antigens was carried out in 47 healthy subjects and 89 patients with acute or chronic viral hepatitis. The results showed that the positive rate of anti HEV IgG in healthy subjects was 4.2%(2/47), and no IgM antibody to HEV was found. The positive rates of IgG and IgM antibodies to HEV in the hepatitis patients were 8.9% and 10% respectively. In addition, we compared the detecting efficacy of the synthetic antigens with that of the market reagent in 57 serum samples, the total coincident rate was 87.7% (50/57). All of the results accorded with the literatures reported. This study suggests that the ELISA based on the synthetic peptide antigens was specific, sensitive and convenient in diagnosis of HEV infection, it can be widely used in both clinical and epidemiological reseaches.     

羊抗人IgG的纯化及其在抗—HCV检测中的应用

单独或联合应用辛酸沉淀、饱和硫酸铵沉淀、阴离子交换等方法对羊抗人IgG进行纯化,对纯化前后抗体的纯度和免疫学活性进行比较,并与辣根过氧化物酶连接,作为二抗用于抗－HCV的ELISA检测。结果表明,不同方法纯化的抗体其纯度和免疫学活性具有一定程度的差别,其中经辛酸＋饱和硫酸铵沉淀纯化的抗体为最佳,凝胶扫描纯度为98．05％,比活性近1800,为纯化前的6．8倍。用痞根过氧化物酶标记后,作为酶标二抗检测HCV阴性和阳性标准血清各40份,阴性符合率为97．5％,阳性符合率为95％,可用于抗－HCV的ELISA检测。     

一种基于配体肽的CRP荧光检测探针的研制

C反应蛋白（C-reaction protein,CRP）是反映机体炎症的有效标志物,早期检测是判断炎症相关疾病的关键,因此,研制CRP新型检测制剂具有重要意义。利用噬菌体表面展示技术对CRP特异性亲和配体进行了筛选,采用固相肽合成技术对目标配体进行了合成,并经生物标记、高效液相色谱法（high performance liquid chromatography,HPLC）分析及质谱（mass spectrometry,MS）鉴定,成功制得检测CRP的荧光探针。经3轮筛选、ELISA检测、重组噬菌体测序及序列比对后得到1个目标配体肽：S-P-H-N-R-S-N-L-V-Q-E-L;经肽合成及生物标记获得1种CRP荧光探针：FITC-（Acp）-S-P-H-N-R-S-N-L-V-Q-E-L。研究结果为CRP的有效检测提供了一种新型制剂。     

Relative bioactivities of cholecystokinins-8 and -33 on rat pancreatic acini

The relative potencies of cholecystokinin (CCK-33) and its carboxyl terminal octapeptide (CCK-8) for stimulation of amylase release from rat pancreatic acini was measured. Porcine CCK-33 and synthetic CCK-8 were initially subjected to high pressure liquid chromatography to assess purity. Concentrations of each peptide were determined by amino acid analysis. The relative immunoreactivities of CCK-33 and CCK-8 were compared using an antibody that recognizes the common carboxyl terminus of these forms. This antibody bound CCK-8 and CCK-33 with nearly equal affinity. The relative potencies of CCK-33 and CCK-8 were then measured by comparing their abilities to stimulate amylase release from isolated rat pancreatic acini. Statistical analysis of the relative potencies of the two hormones indicated that CCK-8 was 36% more potent than CCK-33 in this assay system. These data suggest that differences in biological activities between large and small forms of CCK are not as great as previously reported.     

Synthesis and biological properties of ovine corticotropin-releasing factor (CRF)

The 41-residue sequence of recently identified ovine corticotropin-releasing factor (CRF) was assembled on a benzhydrylamine resin support. Deprotection and cleavage from the resin were accomplished by HF treatment. The crude peptide was purified by gel filtration and reverse-phase, medium pressure, followed by high-performance liquid chromatography (HPLC). In addition to the usual criteria, the homogeneity of the final material, obtained in 7% yield, was assessed by the isolation and examination of cyanogen bromide cleavage and tryptic digestion fragments by HPLC and amino acid analysis. The synthetic 41 amino acid CRF stimulated the release of corticotropin (ACTH) in three in vitro systems: isolated rat pituitary quarters, monolayer cultures of dispersed pituitary cells, and superfused pituitary cells on a column, the responses being related to the log-dose of CRF in the range of 0.05-125 ng/ml. The synthetic peptide also augmented in vivo release of ACTH in rats pretreated with chlorpromazine, morphine, and Nembutal, as assessed by the measurement of serum corticosterone. The data indicates chemical purity and high biological activity of synthetic material.     

Insights on the amino acid side-chain interactions of a synthetic T-cell determinant.

The effect of single amino acid substitutions at positions 18 and 20 on the T-cell determinant (TD) character of peptide p12-26 from lambda repressor protein and on its recognition by a monoclonal antibody was studied by means of 40 synthetic peptides of a length of 15 amino acids. ELISA competition experiments showed that the identity of amino acid at position 20 is very important for antibody recognition, whereas that of amino acid at position 18 is much less important. In contrast, both Leu 18 and Ala 20 are important residues in defining the TD character of peptide p12-26. The most tolerated replacements, ordered in increasing disrupting power are: Ala 20 by Cys, Ser or Gly and Leu 18 by Ile or Val. Any other amino acid replacement completely abolishes the TD capacity of peptide p12-26. The peptides used in this study were synthesized using a multiple solid-phase peptide synthesizer newly designed. Their purity was very high as shown by amino acid sequence experiments.     

Conjugation with α-linolenic acid improves cancer cell uptake and cytotoxicity of doxorubicin

The synthetic DOX–LNA conjugate was characterized by proton nuclear magnetic resonance and mass spectrometry. In addition, the purity of the conjugate was analyzed by reverse-phase high-performance liquid chromatography. The cellular uptake, intracellular distribution, and cytotoxicity of DOX–LNA were assessed by flow cytometry, fluorescence microscopy, liquid chromatography/electrospray ionization tandem mass spectrometry, and the tetrazolium dye assay using the in vitro cell models. The DOX–LNA conjugate showed substantially higher tumor-specific cytotoxicity compared with DOX.     

Photoreactive enkephalin analogue: [D-Ala2, p-N3-Phe4-Met5]-enkephalin. Synthesis, purification by high performance liquid chromatography and characterization

A photoreactive [D-Ala2, p-N3-Phe4-Met5]enkephalin was synthesized by classical solution peptide synthetic methods. The hydroxysuccinimide ester was used in all the coupling steps in the presence of a weak base, triethylamine. The deprotected enkephalin analogue was purified on high performance liquid chromatography using a Waters, C18 muBondapak reverse phase column and its purity was assessed by thin-layer chromatography. The composition of the analogue was determined and confirmed by elemental analysis and amino acid analysis. Its photoreactivity was demonstrated by the time dependent ultraviolet spectral changes on exposure to light. Competition receptor binding showed that [D-Ala2, p-N3-Phe4-Met5]enkephalin was 4-fold more potent than [D-Ala2, Met5]-enkephalin in competing for binding to the enkephalin binding site. The data presented suggest that this photoreactive enkephalin analogue may be suitable for use in the in situ photoaffinity labeling of the enkephalin receptor.